Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
NEWLINK GENETICS (NQ: NLNK)
21.74 USD  +0.11 (+0.51%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 21.70
Bid (Size) 21.74 (800)
Ask (Size) 21.78 (100)
Prev. Close 21.63
Today's Range 21.50 - 22.26
52wk Range 10.60 - 22.26
Shares Outstanding 25,604,839
Dividend Yield N/A
Top News
More News
UPDATE: Jefferies Initiates NewLink Genetics at Buy on Immunotherapy Platform Upside
June 14, 2013
In a report published Friday, Jefferies analyst Biren Amin initiated coverage on NewLink Genetics (NASDAQ: NLNK ) with a Buy rating and $29.00 price target. In the report, Jefferies noted, “We believe... Read More
category Benzinga , Initiation , Biren Amin , and 4 more.
from Latest Articles from Benzinga.com
UPDATE: Jefferies Starts NewLink Genetics (NLNK) at Buy
June 14, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8415740 for the full story. Read More
from StreetInsider.com News Articles

More News
Read More
New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics
June 13, 2013
from PR Newswire
Benzinga's Volume Movers
June 10, 2013
category volume movers , DIN , Benzinga , and 7 more.
from Latest Articles from Benzinga.com
NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
June 03, 2013
category Other News , BIOTECHNOLOGY
from Latest eTeligis Press Releases with 'Plus' ranking
NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer
June 03, 2013
category Other News , BIOTECHNOLOGY
from Latest eTeligis Press Releases with 'Plus' ranking
NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
June 03, 2013
category Other News , BIOTECHNOLOGY
from Latest eTeligis Press Releases with 'Plus' ranking
NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
June 03, 2013
from PR Newswire
NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer
June 03, 2013
from PR Newswire
NewLink (NLNK) Issues Encouraging Update to Tergenpumatucel-L Phase 2
June 03, 2013
from StreetInsider.com News Articles
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here